Open Nav

Tuesday, January 29th, 2013, 9:30-10:25am
Coriander Room

Over the past 12 months, Takeda has acquired five diverse biopharma companies as it looks to enhance its global footprint.  How do the additions of several marketed and pipeline drugs amplify Takeda’s portfolio and how has management integrated with these new entities?  Join us for a fireside chat with a senior business development executive from Takeda to learn about the deal-making details, how these acquisitions play into Takeda’s global strategy, and what Takeda has in store for 2013 and beyond.


  • David Low, Managing Director, Lazard & Co.


  • Ken Araki, Vice President, Corporate Development, Global Business Development, Takeda Pharmaceutical Company



Ken Araki

Vice President, Corporate Development, Global Business Development, Takeda Pharmaceutical Company

Since January 2012, Ken Araki has been in charge of managing Takeda’s global corporate development activities, including M&A and the Japan Business Development Group in charge of Japan/North Asia local transactions and global discovery research collaborations.

Prior to Araki’s current role, he initiated and managed global corporate-wide strategic projects in Takeda’s Corporate Strategy and Planning Department, supporting Takeda’s Senior Management team including the President & CEO. While in this role from 2009 to 2011, he successfully executed the acquisition of Nycomed and was involved in integrating the company into Takeda’s organization. Ken joined Takeda in 2006 as Head of M&A. During his tenure, he successfully executed the acquisition of Millennium Pharmaceuticals and its subsequent integration into Takeda’s organization.

Prior to joining Takeda, he worked on the Investment Banking team at Nomura Securities, the largest firm in Japan. During his tenure, he acted as financial advisor, helping create Daiichi-Sankyo, one of Japan’s largest pharmaceutical companies. He spent over ten years at Nomura as a sell-side analyst, gaining extensive experience as he analyzed the pharmaceutical and biotech industries globally and allowing him to produce many writings and lectures on the industry. He also played a central role in Global Pharmaceutical Equity Research in New York between 1996 and 2004. From 1989 to 1996 he held a series of positions with Nomura Research Institute, a subsidiary of Nomura Securities, including the position of equity analyst following the electronics industry.

Araki holds a Bachelor of Law degree from Kyushu University. He is married with two young daughters and his favorite hobby is spending time with his family.

David Low

Managing Director, Lazard & Co.

David Low joined Lazard's Life Sciences Group in 2002 as a Managing Director based in San Francisco.  Mr. Low has had a long career in Biotech M&A, advising on transactions including Roche’s restructuring of its Genentech ownership (1995 and 1999/2000), Johnson & Johnson’s acquisition of Centocor(1999) and Gilead’s acquisition of Myogen(2006), among others.  On the financing side, Mr. Low has extensive experience with debt and equity, convertibles, R&D financings, private placements and royalty transactions for biotech companies.

Prior to joining Lazard, Mr. Low worked at Lehman Brothers from 1987 to 1996 and JP Morgan from 1996 through July 2002. 

Harvard College, B.A., Johns Hopkins University, M.A. in International Economics, Yale University, M.B.A.